140 related articles for article (PubMed ID: 8878567)
1. Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine.
Zhu YQ; Remington KM; North TW
Antimicrob Agents Chemother; 1996 Sep; 40(9):1983-7. PubMed ID: 8878567
[TBL] [Abstract][Full Text] [Related]
2. A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine.
Smith RA; Remington KM; Preston BD; Schinazi RF; North TW
J Virol; 1998 Mar; 72(3):2335-40. PubMed ID: 9499094
[TBL] [Abstract][Full Text] [Related]
3. Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine.
Remington KM; Chesebro B; Wehrly K; Pedersen NC; North TW
J Virol; 1991 Jan; 65(1):308-12. PubMed ID: 1845891
[TBL] [Abstract][Full Text] [Related]
4. Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.
Medlin HK; Zhu YQ; Remington KM; Phillips TR; North TW
Antimicrob Agents Chemother; 1996 Apr; 40(4):953-7. PubMed ID: 8849258
[TBL] [Abstract][Full Text] [Related]
5. Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase.
Remington KM; Zhu YQ; Phillips TR; North TW
J Virol; 1994 Feb; 68(2):632-7. PubMed ID: 7507182
[TBL] [Abstract][Full Text] [Related]
6. In vitro characterization of FIV-pPPR, a pathogenic molecular clone of feline immunodeficiency virus, and two drug-resistant pol gene mutants.
McCrackin Stevenson MA; McBroom DG
Am J Vet Res; 2001 Apr; 62(4):588-94. PubMed ID: 11327469
[TBL] [Abstract][Full Text] [Related]
7. Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.
Gobert JM; Remington KM; Zhu YQ; North TW
Antimicrob Agents Chemother; 1994 Apr; 38(4):861-4. PubMed ID: 8031060
[TBL] [Abstract][Full Text] [Related]
8. A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.
Smith RA; Remington KM; Lloyd RM; Schinazi RF; North TW
J Virol; 1997 Mar; 71(3):2357-62. PubMed ID: 9032372
[TBL] [Abstract][Full Text] [Related]
9. An HIV-1 215V mutant shows increased phenotypic resistance to d4T.
Pernas M; López-Galíndez C
Virus Res; 2008 Aug; 135(2):340-4. PubMed ID: 18482778
[TBL] [Abstract][Full Text] [Related]
10. In vitro study of resistance-associated genotypic mutations to nucleoside analogs.
Gashnikova N; Plyasunova O; Kiseleva Y; Fedyuk N; Pokrovsky A
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):991-4. PubMed ID: 14565328
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
12. Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay.
Ueno T; Mitsuya H
Biochemistry; 1997 Feb; 36(5):1092-9. PubMed ID: 9033399
[TBL] [Abstract][Full Text] [Related]
13. The mutation frequency of feline immunodeficiency virus enhanced by 3'-azido-3'-deoxythymidine.
LaCasse RA; Remington KM; North TW
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 May; 12(1):26-32. PubMed ID: 8624757
[TBL] [Abstract][Full Text] [Related]
14. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
Gao WY; Johns DG; Tanaka M; Mitsuya H
Mol Pharmacol; 1999 Mar; 55(3):535-40. PubMed ID: 10051538
[TBL] [Abstract][Full Text] [Related]
15. The valine-to-threonine 75 substitution in human immunodeficiency virus type 1 reverse transcriptase and its relation with stavudine resistance.
Selmi B; Boretto J; Navarro JM; Sire J; Longhi S; Guerreiro C; Mulard L; Sarfati S; Canard B
J Biol Chem; 2001 Apr; 276(17):13965-74. PubMed ID: 11134027
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC
Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024
[TBL] [Abstract][Full Text] [Related]
17. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
[TBL] [Abstract][Full Text] [Related]
18. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
19. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.
Lennerstrand J; Stammers DK; Larder BA
Antimicrob Agents Chemother; 2001 Jul; 45(7):2144-6. PubMed ID: 11408240
[TBL] [Abstract][Full Text] [Related]
20. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.
Norelli S; El Daker S; D'Ostilio D; Mele F; Mancini F; Taglia F; Ruggieri A; Ciccozzi M; Cauda R; Ciervo A; Barreca ML; Pistello M; Bendinelli M; Savarino A
Curr HIV Res; 2008 Jun; 6(4):306-17. PubMed ID: 18691029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
